Monkeys Cloned by Dolly-the-Sheep Technology

The approach, which has never before been successfully attempted in primates, could lead to improved animal models for human biology and disease.

Jan 25, 2018
Catherine Offord

Hua Hua, one of two monkeys cloned by somatic cell nuclear transferQIANG SUN & MU-MING POO, CHINESE ACADEMY OF SCIENCESResearchers in China have created the first viable primate clones made using somatic cell nuclear transfer (SCNT), according to a study published yesterday (January 24) in Cell. Two newborn macaques, named Zhong Zhong and Hua Hua, were produced at the Chinese Academy of Sciences’ Institute of Neuroscience (ION) in Shanghai using the same technology made famous by Dolly the Sheep, and could represent a novel model system for scientists studying human biology and disease.

“This paper really marks the beginning of a new era for biomedical research,” Xiong Zhi-Qi, a researcher studying brain disease at the ION but who was not involved in the work, tells Nature.

These monkeys are not the first primates to be cloned. A rhesus macaque named Tetra was produced in the late 1990s by embryo splitting, the division of an early-stage embryo into two or four separate cells to make clones. Zhong Zhong and Hua Hua, by contrast, were each made by replacing an egg cell nucleus with DNA from a differentiated body cell. The technique—which has previously been employed to clone sheep, cattle, cats, mice, and dogs—can create more clones than embryo splitting and allows researchers greater control over the edits they make to the transferred DNA.

Adapting the approach to monkeys proved difficult, and many attempts by the Chinese team failed: the researchers transferred 79 embryos into surrogate monkeys for just two viable births. “The SCNT procedure is rather delicate,” study coauthor Mu-ming Poo, director of ION, says in a statement. “The faster you do it, the less damage to the egg you have. . . . It is likely that the optimization of transfer procedure greatly helped us to achieve this success.”

Many researchers have been quick to pour water on the idea that the team’s results bring scientists closer to cloning humans. “The work in this paper is not a stepping stone to establishing methods for obtaining live born human clones,” Robin Lovell-Badge of the Francis Crick Institute in London tells reporters (via the The Independent). This clearly remains a very foolish thing to attempt, it would be far too inefficient, far too unsafe, and it is also pointless.”

But Poo emphasizes that this is not the team’s goal. “There is now no barrier for cloning primate species, thus cloning humans is closer to reality,” Poo tells reporters (via The Guardian). “However, our research purpose is entirely for producing non-human primate models for human diseases; we absolutely have no intention, and society will not permit, this work to be extended to humans.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!